Got a Billion Cells? Illumina Does

Illumina's CRISPR-powered Billion Cell Atlas maps 1 billion cell responses across 200+ disease lines to sharpen AI drug discovery

27 Mar 2026

Drug discovery has long relied on a frustrating shortcut: finding genes that correlate with disease and hoping the biology cooperates. Illumina thinks it has a better way.

On January 13, 2026, the genomics giant launched the Billion Cell Atlas, a genome-wide resource mapping how one billion human cells respond to targeted gene edits across more than 200 disease-relevant cell lines. The goal is to give pharmaceutical AI models something they've been sorely missing: real biological signal, not just statistical pattern-matching.

The Atlas uses CRISPR to switch individual genes on or off, capturing each cellular response at single-cell resolution. That process links roughly 20,000 human genes to measurable effects in cells tied to cancer, immune disease, neurology, cardiometabolic conditions, and rare disorders. It's the difference between watching how genes actually behave and guessing based on population-level correlations.

Three major pharmaceutical companies are already in. Merck plans to train AI models on the dataset to surface precision biomarkers grounded in real biological variation. AstraZeneca is using it to turn genetic associations into testable hypotheses about disease mechanisms. A wave of additional pharma and tech companies reportedly contacted Illumina the day of the announcement, a sign of how acutely the sector has felt the absence of this kind of resource.

The Atlas is the debut product from BioInsight, Illumina's new business unit focused on datasets and AI tools for drug discovery. The company plans to scale to five billion cells over three years, with 20 petabytes of single-cell transcriptomic data expected in year one alone.

Skeptics will note the genuine gap between cell-line data and real patient biology. It's a fair point, and one the field will need to keep pressure-testing. But with three major partners already weaving the Atlas into active discovery pipelines, Illumina isn't waiting for the debate to settle. The infrastructure is being built now, and the rest of the industry appears eager to build on it.